Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 7, 2014, Pages 1356-1365

  Knipe, Duleeka W ^a   Evans, David M ^a,b   Kemp, John P ^a,b   Eeles, Rosalind ^c,d   Easton, Douglas F ^e   Kote Jarai, Zsofia ^c,d   Al Olama, Ali Amin ^e   Benlloch, Sara ^e   Donovan, Jenny L ^a   Hamdy, Freddie C ^f   Neal, David E ^d,e   Smith, George Davey ^a,b   Lathrop, Mark ^g,h   Martin, Richard M ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^h MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALLELE; ARTICLE; CHROMOSOME 10Q; CHROMOSOME 17Q; CHROMOSOME 19Q; CHROMOSOME 8Q; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; META ANALYSIS; MIDDLE AGED; PROSTATE TUMOR;

AGED; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84904001854     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0889     Document Type: Article

References (26)

1. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or 4.0 ng per milliliter. N Engl J Med 2004;350: 2239-6.
2. Eeles RA, Al Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013;45: 385-91.
3. Cheng I, Chen GK, Nakagawa H, He J, Wan P, Laurie CC, et al. Evaluating genetic risk for prostate cancer among Japanese and Latinos. Cancer Epidemiol Biomarkers Prev 2012;21: 2048-8.
4. Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007;99: 1836-4.
5. Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, et al. Identification of seven newprostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009;41: 1116-1.
6. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40: 316-1.
7. Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, Gylfason A, Agnarsson BA, et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 2009;41: 1122-6.
8. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39: 631-7.
9. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007;39: 977-83.
10. Sun J, Zheng SL, Wiklund F, Isaacs SD, Li G, Wiley KE, et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res 2009;69: 10-5.
11. Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N, Kawaguchi T, et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet 2010;42: 751-4.
12. Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S, et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 2011;20: 3867-75.
13. FitzGerald LM, Kwon EM, Conomos MP, Kolb S, Holt SK, Levine D, et al. Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2011;20: 1196-03.
14. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 2011;43: 570-3.
15. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011;43: 785-91.
16. Nam RK, ZhangWW,Trachtenberg J, Seth A, Klotz LH, Stanimirovic A, et al. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res 2009;15: 1787-93.
17. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008;40: 310-5.
18. Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009;41: 1058-60.
19. Gudmundsson J, Besenbacher S, Sulem P, Gudbjartsson DF, Olafsson I, Arinbjarnarson S, et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2010;2: 62ra92.
20. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 2010;46: 3095-1.
21. Ohori M, Wheeler TM, Scardino PT. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer 1994;74: 104-4.
22. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010;34: 816-4.
23. Li Y, Willer C, Sanna S, Abecasis G. Genotype imputation. Annu Rev Genomics Hum Genet 2009;10: 387-06.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-Analyses. BMJ 2003;327: 557-60.
25. Nam RK, Zhang W, Siminovitch K, Shlien A, Kattan MW, Klotz LH, et al. New variants at 10q26 and 15q21 are associated with aggressive prostate cancer in a genome-wide association study from a prostate biopsy screening cohort. Cancer Biol Ther 2011;12: 997-4.
26. Zackrisson B, Aus G, Lilja H, Lodding P, Pihl CG, Hugosson J. Followup of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening. Eur Urol 2003;43: 327-2.